COMPARE ANTIVIRAL EFFICACY OF ORALTDF & SUBCUTANEOUSTFV IN SIV-INFECTED MACAQUES

比较 ORALTDF 的抗病毒功效

• 批准号: 8357301
• 负责人: KOEN K VAN ROMPAY
• 金额: $ 19.14万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357301
• 关键词: Antiviral Agents; California; Drug Kinetics; Fumarates; Funding; Grant; Macaca; National Center for Research Resources; Primates; Principal Investigator; Prodrugs; Research; Research Infrastructure; Resources; SIV; Source; Tenofovir; United States National Institutes of Health; cost

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The study will compare the antiviral efficacy and pharmacokinetics of the parenteral compound tenofovir and its prodrug tenofovir disoproxyl fumarate in groups of SIV-infected macaques.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 该研究将比较肠胃外化合物替诺福韦及其前药富马酸替诺福韦二吡呋酯在感染 SIV 的猕猴组中的抗病毒功效和药代动力学。